DE68915165T2 - Schimärische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3. - Google Patents

Schimärische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.

Info

Publication number
DE68915165T2
DE68915165T2 DE68915165T DE68915165T DE68915165T2 DE 68915165 T2 DE68915165 T2 DE 68915165T2 DE 68915165 T DE68915165 T DE 68915165T DE 68915165 T DE68915165 T DE 68915165T DE 68915165 T2 DE68915165 T2 DE 68915165T2
Authority
DE
Germany
Prior art keywords
gene
glycoprotein
fragment
plasmid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68915165T
Other languages
English (en)
Other versions
DE68915165D1 (de
Inventor
Michael Wathen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of DE68915165D1 publication Critical patent/DE68915165D1/de
Publication of DE68915165T2 publication Critical patent/DE68915165T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (10)

1. Polypeptid, enthaltend mindestens ein immunogenes Fragment von den beiden Glycoproteinen F und HN des humanen Parainfluenza-Virus vom Typ 3.
2. Polypeptid nach Anspruch 1, das zusätzlich eine Signalsequenz enthält.
3. Polypeptid nach Anspruch 2, das, beginnend mit dem N- terminalen Ende, die Signalsequenz des Glycoproteins F, ein immunogenes Fragment des Glycoproteins F und ein immunogenes Fragment des Glycoproteins HN enthält.
4. Humanvaccine, enthaltend ein Polypeptid nach einem der voranstehenden Ansprüche.
5. Verwendung eines Polypeptids nach einem der voranstehenden Ansprüche für die Herstellung eines Impfstoffs für den Gebrauch zum Schutz von Menschen vor dem humanen Parainfluenza-Virus vom Typ 3.
6. Expressionssystem, umfassend einen geeigneten Wirt, welches eine DNA-Sequenz enthält, das in der Lage ist, ein Polypeptid nach einem der Ansprüche 1 - 3 zu exprimieren.
7. Expressionssystem nach Anspruch 6, worin der Wirt unter Bakterienzellen, Hefezellen, Säugerzellen und Insektenzellen, z. B. E. coli-Bakterien, Ovariumzellen des chinesischen Hamsters, von der Maus stammenden C127-Zellen oder S. frugiperda-Zellen ausgewählt ist.
8. Expressionssystem nach Anspruch 6 oder 7, worin der Wirt in der Lage ist, das Polypeptid zu sezernieren.
9. Expressionssystem nach einem der Ansprüche 6 bis 8, worin die DNA-Sequenz in einem Plasmid enthalten ist, das sich unter der Kontrolle eines Cytomegalovirus-Promotors, oder, in einem eukaryontischen Wirt, von Rinder-Papillomavirus-DNA-Sequenzen befindet.
10. Expressionssystem nach einem der Ansprüche 6 bis 8, worin die DNA-Sequenz in einem rekombinanten Virus der Baculovirus-Familie, z. B. Autographa californica Kernpolyhedrosis-Virus, enthalten ist.
DE68915165T 1988-04-22 1989-03-03 Schimärische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3. Expired - Lifetime DE68915165T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18464888A 1988-04-22 1988-04-22
PCT/US1989/000814 WO1989010405A1 (en) 1988-04-22 1989-03-03 Chimeric glycoproteins containig immunogenic segments of human parainfluenza virus type 3

Publications (2)

Publication Number Publication Date
DE68915165D1 DE68915165D1 (de) 1994-06-09
DE68915165T2 true DE68915165T2 (de) 1994-09-08

Family

ID=22677770

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68915165T Expired - Lifetime DE68915165T2 (de) 1988-04-22 1989-03-03 Schimärische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.

Country Status (12)

Country Link
US (2) US5169628A (de)
EP (1) EP0413695B1 (de)
KR (1) KR970009347B1 (de)
AT (1) ATE105334T1 (de)
AU (1) AU611784B2 (de)
CA (1) CA1306709C (de)
DE (1) DE68915165T2 (de)
DK (1) DK172635B1 (de)
FI (1) FI102616B (de)
HK (1) HK37397A (de)
NO (1) NO303499B1 (de)
WO (1) WO1989010405A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486599A (en) * 1989-03-29 1996-01-23 The Board Of Trustees Of The Leland Stanford Junior University Construction and use of synthetic constructs encoding syndecan
GB8914968D0 (en) * 1989-06-29 1989-08-23 Connaught Lab Production of virus and purification of viral envelope proteins for vaccine use
JP2649285B2 (ja) * 1990-11-29 1997-09-03 藤倉化成株式会社 ヒトパラインフルエンザ４ａ型ウイルスフュージョンプロテイン遺伝子及び該遺伝子を含む物質
GB9120221D0 (en) * 1991-09-23 1991-11-06 Smithkline Beecham Biolog Novel compounds
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5550017A (en) * 1993-10-12 1996-08-27 Emory University Anti-paramyxovirus screening method and vaccine
DE69534077T2 (de) * 1994-01-14 2005-08-11 Rath, Matthias, Dr.med. Verwendung von methoden zur identifizierung von hydrophilen signal-oligopeptiden
US7300918B2 (en) 1994-01-14 2007-11-27 Matthias Rath Method of producing vaccines from protein signal oligopeptides
US5869036A (en) * 1995-12-08 1999-02-09 St. Louis University Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine
EP1019435A4 (de) * 1996-01-29 2001-12-12 Univ Georgetown Amplifizierung der wirksamkeit exprimierter rekombinanter proteine
FR2751229B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
US6060308A (en) 1997-09-04 2000-05-09 Connaught Laboratories Limited RNA respiratory syncytial virus vaccines
AU749345B2 (en) 1997-11-14 2002-06-27 Connaught Laboratories Limited Alphavirus vectors for paramyxovirus vaccines
DE60041183D1 (de) 1999-05-06 2009-02-05 Univ Wake Forest Zusammensetzungen und methoden zur identifikation von antigenen, die eine immunantwort hervorrufen
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
KR100964413B1 (ko) 2001-01-19 2010-06-15 비로노바티브 비.브이. 감응성 포유류에서 호흡계 질환을 유발하는 바이러스
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
EP2327418A1 (de) 2002-02-21 2011-06-01 MedImmune, LLC Rekombinante Parainfluenza Virus basierte Expressions Systeme und Impfstoffe, die heterologe Antigene von anderen Viren enthalten
EP2494986A1 (de) 2003-04-25 2012-09-05 MedImmune Vaccines, Inc. Metapneumovirusstämme und deren Verwendung in Impfstoffformulierungen und als Vektoren für die Expression antigener Sequenzen und Verfahren zur Ausbreitung des Virus
MXPA05012542A (es) * 2003-06-05 2006-02-08 Wyeth Corp Composiciones inmunogenicas que comprenden vectores de replicon del virus de la encefalitis equina venezolana y antigenos de la proteina del paramixovirus.
EP4349404A3 (de) 2015-10-22 2024-06-19 ModernaTX, Inc. Impfstoffe gegen respiratorische viren
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US20230036213A1 (en) * 2019-12-10 2023-02-02 Children's National Medical Center T-cell epitopes of human parainfluenza virus 3 for adoptive t-cell immunotherapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743553A (en) * 1984-07-18 1988-05-10 W. R. Grace & Co. Synthetic genes for bovine parainfluenza virus
JP2564268B2 (ja) * 1985-08-28 1996-12-18 協和醗酵工業株式会社 融合抗原ポリペプチド
US4790987A (en) * 1985-11-15 1988-12-13 Research Corporation Viral glycoprotein subunit vaccine
NZ230425A (en) * 1988-09-02 1992-07-28 Molecular Eng Ass Production of paramyxovirus fusion (f) protein using recombinant baculovirus expression vector

Also Published As

Publication number Publication date
EP0413695B1 (de) 1994-05-04
CA1306709C (en) 1992-08-25
DK172635B1 (da) 1999-03-22
AU611784B2 (en) 1991-06-20
FI905184A0 (fi) 1990-10-19
JPH03503760A (ja) 1991-08-22
NO904538D0 (no) 1990-10-19
FI102616B1 (fi) 1999-01-15
US5169628A (en) 1992-12-08
ATE105334T1 (de) 1994-05-15
NO904538L (no) 1990-12-27
FI102616B (fi) 1999-01-15
NO303499B1 (no) 1998-07-20
KR970009347B1 (en) 1997-06-10
DK251890A (da) 1990-10-18
KR900700613A (ko) 1990-08-16
US5284764A (en) 1994-02-08
DK251890D0 (da) 1990-10-18
WO1989010405A1 (en) 1989-11-02
EP0413695A1 (de) 1991-02-27
DE68915165D1 (de) 1994-06-09
HK37397A (en) 1997-04-04
AU3197589A (en) 1989-11-24

Similar Documents

Publication Publication Date Title
DE68915165T2 (de) Schimärische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
DE3878468T2 (de) Chimarenglykoproteine, enthaltend immunogene segmente des humanen respiratorischen synzytialvirus.
US5149650A (en) Vaccines for human respiratory virus
DE69017769T2 (de) Verbindungen.
DE69016956T2 (de) Rekombinantes Truthahn-Herpesvirus und davon abgeleiteter Lebendimpfstoffvektor.
DE3888086T2 (de) Rekombinantes Geflügelpockenvirus, Expressionsvektoren für heterologische Proteine und davon derivierte Geflügelvakzine.
DE3587991T2 (de) Rekombinanter herpes simplex gb-gd impfstoff.
DE69121746T2 (de) Rekombinante Herpes-Viren, besonders zur Herstellung von Impfstoffen, Verfahren zur Herstellung davon, während des Prozesses hergestellte Plasmide und durchgesetzte Impfstoffe
DE69115653T2 (de) Eine prokaryotische Leader-Sequenz enthaltendes Bakuloviren-Exprimierungssystem
AU605476B2 (en) Vaccines for human respiratory virus
DE69434413T2 (de) Fusionsproteine zwischen antigene aminosäuresequenzen und beta - 2- mikroglobulin
DE3853139T2 (de) Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung.
DE69330238T2 (de) Verfahren zur Herstellung des Ectoproteins des Hepatitis-C-Virus
DE69331551T2 (de) Rinder-"hitzeschock"-promoter und dessen verwendung
DE69534162T2 (de) Fusion-glykoprotein von hcmv und hsv
DE3586830T2 (de) Verfahren zur ligation von heterogenen genen.
DE69217614T2 (de) Hybride, lösliche und nicht gespaltene gp160-variante
DE69332480T2 (de) Impfstoff-vektoren von rekombinantem katzen-herpesvirus
EP0284791B1 (de) DNA- und RNA-Moleküle des westlichen Subtyps des FSME-Virus, Polypeptide, die von diesen Molekülen codiert werden, und deren Verwendung
DE3850323T2 (de) Virusvektor und Rekombinante DNS, die ein oder mehrere strukturelle Proteine (HA,F und/oder NP) eines Morbillivirus Kodieren.
JP3026986B2 (ja) ヒト・パラインフルエンザウイルス３型の免疫原性セグメント類を含有するキメラ糖蛋白類
DE3588244T2 (de) Rekombinanter Herpes Simplex gB-gD-Impfstoff

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: PHARMACIA & UPJOHN CO., KALAMAZOO, MICH., US